A response to an ADC therefore cannot by itself be treated as proof that tumor immunity has been activated. The most clearly established mechanism is antigen-dependent delivery. After binding its target, an ADC is internalized and trafficked intracellularly, where processing enables payload release.

Released cytotoxic agents can kill directly targeted cells, while bystander killing can extend exposure to neighboring tumor cells that may have lower antigen expression. This effect broadens cytotoxic activity, but it does not distinguish the contribution of direct damage from that of systemic or local immune responses. The review also finds that payload-induced stress or DNA damage can generate immunogenic-cell-death signals in selected preclinical systems, engage the cGAS–STING pathway, preserve Fcγ receptor-dependent effector functions and support antigen presentation.

These observations remain platform- and context-dependent and have not been uniformly demonstrated in patients. STING agonist ADCs represent a different design. Rather than relying only on a payload that kills tumor cells, these agents are intended to deliver an innate immune agonist to antigen-bearing tumors.

In mouse models, tumor-targeted STING conjugates activated STING signaling in tumor and myeloid compartments, showing that localized innate immune stimulation is possible. Their clinical value in breast cancer, however, remains investigational. Evidence for immune remodeling is strongest as a mechanistic or model-based observation, not as a demonstrated explanation for human treatment responses.

Antibody trafficking adds another layer of complexity. The neonatal Fc receptor, FcRn, rescues IgG that is pinocytosed into acidic endosomes and consequently influences antibody exposure and tissue disposition. Wild-type IgG uptake at neutral pH is predominantly fluid-phase, while engineered variants with residual neutral-pH FcRn binding may increase uptake in environments where FcRn is abundant.

For ADC biology, uptake, intracellular routing and delivery to the appropriate compartment are integral to payload action. The review treats FcRn-related variables as potentially informative, but not yet established as determinants of routine ADC selection. Current biomarker practice also leaves important questions unresolved.

HER2 and TROP2 immunohistochemistry can document the presence of a target, but it does not quantify accessible membrane antigen with enough precision to establish receptor abundance, internalization, ADC delivery or the immune contribution to efficacy. Quantitative continuous scoring and membrane-localization measurements are described as promising, but they require prospective, breast-cancer-specific validation. A rigorous assessment must separately characterize antigen abundance and localization, ADC delivery and trafficking, payload pharmacology and serial immune changes, while also evaluating target-independent toxicity.

Until mechanism-linked sampling and prospective studies establish these relationships, ADC efficacy should not be interpreted as evidence of immune activation, and neither FcRn variables nor quantitative antigen metrics are sufficiently validated to guide routine ADC selection.

Subject of Research: Mechanisms and immune effects of antibody–drug conjugates in breast cancer

Article Title: Antibody–drug conjugates and tumor immunity in breast cancer

Article References: Kashiwagi, S. (2026). Antibody–drug conjugates and tumor immunity in breast cancer. Medical Oncology, 43(11), Article 345. https://doi.org/10.1007/s12032-026-03458-5

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03458-5

Keywords: antibody–drug conjugates, breast cancer, tumor immunity, HER2, TROP2, HER3, STING signaling, FcRn, immunogenic cell death, ADC biomarkers, Antibody, drug

The clinical stakes of the finding are considerable. Patients with EGFR-mutated non-small cell lung cancer typically respond well to third-generation EGFR inhibitors such as osimertinib, but resistance almost inevitably emerges, and once progression occurs on these targeted agents, treatment options narrow dramatically. Most patients in the Phase 1 study had already progressed on a third-generation EGFR inhibitor, and nearly two-thirds had also received platinum-based chemotherapy, meaning the antibody-drug conjugate was being tested in one of the most treatment-refractory settings in thoracic oncology. Against that backdrop, the observed activity offers a potential new direction for a population in which each successive line of therapy tends to yield shorter and less durable responses.

The design of the molecule itself reflects a deliberate strategic choice by its developers. Antibody-drug conjugates combine an antibody that homes in on specific proteins on the surface of cancer cells with a cytotoxic payload delivered through a chemical linker. By directing the drug to cells expressing EGFR or HER3, the therapy aims to concentrate its toxic cargo within tumor tissue while sparing healthy cells, at least relative to conventional chemotherapy. Targeting two receptors at once rather than one is intended to broaden coverage across heterogeneous tumors and to reduce the chance that cancer cells escape treatment by simply downregulating a single target. HER3 in particular has attracted attention because it is widely expressed in EGFR-mutated lung cancers and has been implicated in resistance to EGFR-targeted therapy.

Dose finding was a central objective of the study, and the results revealed a clear relationship between dose level and clinical activity, with responses becoming more frequent as the dose increased. At the dose ultimately selected for late-stage development, 2.5 milligrams per kilogram, the objective response rate reached 33.3 percent, and the confirmed objective response rate, which requires shrinkage to be verified on a subsequent scan, stood at 29.6 percent. Median progression-free survival, the average time patients lived before their disease began to grow again, was 6.9 months. For a cohort composed almost entirely of patients whose cancers had already outmaneuvered both a modern EGFR inhibitor and, in many cases, chemotherapy, those figures represent a clinically relevant level of benefit.

Safety has historically been the Achilles heel of therapies directed at EGFR and HER3, because both receptors are expressed to some degree in normal tissues, including the skin, gastrointestinal tract, and blood-forming system. Earlier experience with the investigational conjugate had raised concerns about hematologic toxicity, particularly declines in white blood cell counts that can leave patients vulnerable to infection. The study addressed this risk head-on by making primary prophylaxis with granulocyte colony-stimulating factor, a growth factor that stimulates white blood cell production, a mandatory part of the treatment protocol. This requirement was associated with an improved hematologic safety profile compared with what had been reported previously, demonstrating that thoughtful supportive care can meaningfully widen the therapeutic window of a potent targeted agent.

Beyond the blood counts, the overall tolerability data supported continued development. No deaths attributable to the treatment were observed across the study, and only a single patient discontinued therapy because of a treatment-related adverse event, an unusually low discontinuation rate for an oncology drug in this class. In practice, that means nearly all patients were able to remain on treatment and continue receiving whatever benefit the drug was providing, an important consideration when evaluating the real-world usefulness of a therapy intended for patients who have few remaining options.

The durability and breadth of the responses also carry scientific implications for how the field thinks about resistance to EGFR-targeted therapy. Resistance mechanisms after third-generation EGFR inhibitors are notoriously diverse, ranging from secondary mutations in EGFR itself to lineage shifts that transform the tumor’s behavior entirely. A therapeutic approach that does not depend on a single resistance mechanism, but instead exploits the persistent surface expression of EGFR and HER3 to deliver chemotherapy directly to tumor cells, offers a way to sidestep much of that heterogeneity. The results from the dose-expansion cohort suggest that this strategy can translate into measurable benefit even after multiple lines of prior treatment.

On the strength of these findings, the investigators have selected 2.5 milligrams per kilogram as the recommended Phase 3 dose and are advancing the regimen into IZABRIGHT-Lung01, a global registrational trial designed to test the therapy rigorously in patients with previously treated EGFR-mutated non-small cell lung cancer. Registrational studies of this kind are the decisive step between experimental development and potential regulatory approval, and their design will determine whether the signal seen in the Phase 1 cohort holds up under controlled comparison. Alexander Spira, M.D., of NEXT Oncology Virginia and Virginia Cancer Specialists in Fairfax, Virginia, said the findings support continued development of iza-bren and provide the rationale for advancing the 2.5 milligram per kilogram regimen into the global Phase 3 trial for this patient population.

For the broader lung cancer community, the study is a reminder of how quickly the treatment landscape evolves when rational drug design meets careful clinical optimization. Less than two decades ago, patients with EGFR-mutated lung cancer had no targeted options at all; today the challenge has shifted from initial sensitivity to overcoming resistance, and antibody-drug conjugates have emerged as one of the most promising tools for that second act. The Seoul presentation adds a candidate with dual-target specificity and a feasible safety profile to a competitive field, and the results of IZABRIGHT-Lung01 will determine whether patients whose disease has progressed on EGFR inhibitors gain a genuinely new standard of care. With incidence of lung cancer remaining among the highest of any malignancy worldwide, and with EGFR mutations representing a particularly common driver in Asian populations, the trial’s global scope underscores how consequential the answer may be for patients and clinicians on multiple continents.

The path from a Phase 1 dose-expansion cohort to a registrational program is never guaranteed, and the history of oncology drug development is littered with early signals that failed to confirm in larger, randomized settings. Nevertheless, the combination of objective responses in a heavily pretreated population, a median progression-free survival approaching seven months, no treatment-related deaths, and a supportive-care strategy that demonstrably improved tolerability gives this program a foundation that many earlier attempts at EGFR- and HER3-directed conjugates lacked. As the IZABRIGHT-Lung01 study begins enrolling patients worldwide, researchers and clinicians alike will be watching closely to see whether iza-bren can convert a promising Phase 1 signal into a new therapeutic option for one of the most pressing unmet needs in lung cancer medicine.

Subject of Research: A Phase 1 dose-expansion study of the investigational EGFR x HER3 antibody-drug conjugate iza-bren in previously treated EGFR-mutated non-small cell lung cancer.

Article Title: Phase 1 study supports recommended phase 3 dose for investigational EGFR x HER3 antibody-drug conjugate in EGFR-mutated lung cancer

Article References: Phase 1 study supports recommended phase 3 dose for investigational EGFR x HER3 antibody-drug conjugate in EGFR-mutated lung cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: EGFR-mutated lung cancer, HER3, antibody-drug conjugate, iza-bren, non-small cell lung cancer, EGFR inhibitor resistance, Phase 1 trial, IZABRIGHT-Lung01, objective response rate, progression-free survival, G-CSF prophylaxis, WCLC 2026